Zusammenfassung
Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente gegen Schlafstörungen beschrieben. Diese werden entsprechend den DSM-5- und ICD11-Kriterien neu geordnet. Die Strukturen innerhalb der einzelnen Diagnosen sind geblieben.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Avni T, Reich S, Lev N, Gafter-Gvili A (2019) Iron supplementation for restless legs syndrome – a systematic review and meta-analysis. Eur J Intern Med 63:34–41
Baladi MG, Forster MJ, Gatch MB et al (2018) Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 366:367–376
Bassetti C, Kallweit U, Vignatelli L et al (2021) European guideline and expert statements on the management of narcolepsy in adults and children. J Sleep Res 30:e13387
Borovac JA (2016) Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology. Yale J Biol Med 89:37–47
Dauvilliers Y, Verbraecken J, Partinen M et al (2020) Pitolisant for daytime sleepiness in obstructive sleep apnea patients refusing CPAP: a randomized trial. Am J Respir Crit Care Med 201:1135–1145
De Crescenzo F, D’Alò GL, Ostinelli EG et al (2022) Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet 400:170–184
Dresler M, Spoormaker VI, Beitinger P et al (2014) Neuroscience-driven discovery and development of sleep therapeutics. Pharmacol Ther 141:300–334
Emsellem HA, Thorpy MJ, Lammers GJ et al (2019) Measures of functional outcomes, work productivity, and quality of lifefrom a randomized phase 3 study of solriamfetol in participants with narcolepsy. Sleep Med 67:128
Evans R, Kimura H, Alexander R et al (2022) Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients. Proc Natl Acad Sci USA 119:e2207531119
Garcia-Borreguero D, Cano-Pumarega I (2017) New concepts in the management of restless legs syndrome. BMJ 356:j104
Hayes CA, Kingsley JR, Hamby KR, Carlow J (2008) The effect of endovenous laser ablation on restless legs syndrome. Phlebology 23:112–117
Heidbreder A, Trenkwalder C et al (2022) Restless Legs Syndrom, S2k-Leitlinie. In: Deutsche Gesellschaft für Neurologie, Deutsche Gesellschaft für Schlafforschung und Schlafmedizin (DGSM) (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie
Huddart R, Clarke M, Altman RB, Klein TE (2018) PharmGKB summary: oxycodone pathway, pharmacokinetics. Pharmacogenet Genomics 28(10):230–237
Iftikhar IH, Alghothani L, Trotti LM (2017) Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. Eur J Neurol 24(12):1446–1456
Keks NA, Hope J, Keogh S (2017) Suvorexant: scientifically interesting, utility uncertain. Australas Psychiatry 25:622–624
Klepitskaya O, Lui Y, Sharma S et al (2018) Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease. Neurology 91(11):e1013–e1021
Kunz D, Dauvilliers Y, Benes H et al (2023) Long-term safety and tolerability of daridorexant in patients with insomnia disorder. CNS Drugs 37(1):93–106
Malhotra A, Shapiro C, Pepin JL et al (2020) Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. Sleep 43(2):zsz220
Lang C, Ludolph AC (2021) Stellenwert von Pitolisant in der Behandlung der Narkolepsie. Psychopharmakotherapie 28:251–259
Mayer G (2014) Narkolepsie. Nervenarzt 85:26–34
Mittal SO, Machado D, Richardson D et al (2018) Botulinum toxin in restless legs syndrome – a randomized double-blind placebo-controlled crossover study. Toxins 10(10):E401
Monti JM, Pandi-Perumal SR (2007) Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat 3(4):441–453
Niederschweiberer J, Schumacher NU, Kumpfmüller D et al (2022) Das Anti-IgLON5-Syndrom in der klinischen Neurologie – zwei Fallberichte. Nervenarzt 93:1247–1249
Nissen C, Frase L, Hajak G, Wetter TC (2014) Hypnotika – Stand der Forschung. Nervenarzt 85:67–76
O’Reardon JP, Stunkard AJ, Allison KC (2004) Clinical trial of sertraline in the treatment of night eating syndrome. Int J Eat Disord 35:16–26
Pollmächer T, Wetter TC, Happe S et al (2014) Schlafmedizinische Differenzialdiagnostik in Psychiatrie und Psychotherapie. Nervenarzt 85:57–66
Riemann D, Baglioni C, Feige B, Spiegelhalder K (2014) Insomnien – Stand der Forschung. Nervenarzt 85:43–49
Riemann D, Baglioni C, Bassetti C et al (2017a) European guideline for the diagnosis and treatment of insomnia. J Sleep Res 26:675–600
Riemann D, Baum E, Cohrs S et al (2017b) S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen. Kapitel „Isomnie bei Erwachsenen“. Somnologie 21:2–44
Saper CB, Fuller PM (2017) Wake-sleep circuitry: an overview. Curr Opin Neurobiol 44:186–192
Schweitzer P, Strohl KP, Malhotra A et al (2018) 0622 Solriamfetol (JZP-110) in the treatment of excessive sleepiness in narcolepsy and obstructive sleep apnea: maintenance of wakefulness test results across the day. Sleep 41:A231–A231
Schweitzer PK, Rosenberg R, Zammit GK et al (2019) Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3). A randomized controlled trial. Am J Respir Crit Care Med 199:1421–1431
Silber MH, Becker PM, Buchfuhrer MJ et al (2021) The management of restless legs syndrome: an updated algorithm. Mayo Clin Proc 96(7):1921–1937
Stallman HM, Kohler M, White J (2018) Medication induced sleepwalking: a systematic review. Sleep Med Rev 37:105–113
Steiger A (2018) Tasimelteon reentrains sleep period in a patient with phase delay syndrome. J Sleep Res 27:P62
Steiger A, Pawlowski M, Kimura M (2015) Sleep electroencephalography as a biomarker in depression. Chronophysiol Ther 5:15–25
Suzuki M, Yukitake H, Ishikawa T, Kimura H (2018) An orexin 2 receptor-selective agonist Tak-925 ameliorates narcolepsy-like symptoms in orexin/ataxin-3 mice. Sleep 41:A1
Trenkwalder C, Benes H, Grote L et al (2013) Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 12:1141–1150
Trenkwalder C, Winkelmann J, Inoue Y, Paulus W (2015) Restless legs syndrome – current therapies and management of augmentation. Nat Rev Neurol 11(8):434–445
Trenkwalder C, Winkelmann J, Oertel W, Virgin G, Roubert B, Mezzacasa A (2017) Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Mov Disord 32(10):1478–1482
Winkelmann J, Allen RP, Högl B et al (2018) Treatment of restless legs syndrome: evidence-based review and implications for clinical practice (revised 2017). Mov Disord 33(7):1077–1091
Yang X, Yang B, Ming M et al (2019) Efficacy and tolerability of intravenous iron for patients with restless legs syndrome: evidence from randomized trials and observational studies. Sleep Med 61:110–117
Yukitake H, Fujimoto T, Ishikawa T et al (2019) TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice. Pharmacol Biochem Behav 187:172794
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Steiger, A., Weber, F., Benkert, O. (2023). Medikamente zur Behandlung von Schlafstörungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67685-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-662-67685-1_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-67684-4
Online ISBN: 978-3-662-67685-1
eBook Packages: Medicine (German Language)